Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta
Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta
复制标题
DOI：
10.1007/s10072-007-0803-3
复制
发表时间：
2007-06-01
影响因子：
3.3
通讯作者：
Airas, L.
中科院分区：
文献类型：
--
作者：
Saraste, M.;Irjala, H.;Airas, L.
我们研究了干扰素-β（IFN-β）治疗复发缓解型多发性硬化症（MS）如何影响自然杀伤细胞（NK细胞）亚群。IFN-β治疗后，MS患者外周血中CD 56（Bright）NK细胞扩增，而同时CD 56（Dim）细胞的比例减少。在对照组中，与同一个体的外周血相比，次级淋巴组织中CD 56（Bright）NK细胞的比例显著较高。我们的研究结果证实，CD 56（Bright）NK细胞优选位于次级淋巴组织内，在那里它们可以与T细胞相互作用，从而有助于控制MS的疾病活动。
We studied how interferon-beta (IFN-beta) treatment of relapsing-remitting multiple sclerosis (MS) affects subgroups of natural killer cells (NK cells). Following IFN-beta treatment, there was an expansion of CD56(Bright) NK-cells in the peripheral blood of MS patients, while at the same time the proportion of CD56(Dim) cells was diminished. In a control group, the proportion of CD56(Bright) NK-cells was significantly higher in secondary lymphoid tissues compared to the peripheral blood of the same individual. Our findings confirm that CD56(Bright) NK-cells preferably locate within the secondary lymphoid tismes, where they may interact with T cells and thereby contribute to the control of the disease activity in MS.